Chemokines and chemokine receptors in scleroderma
- PMID: 16804319
- DOI: 10.1159/000094242
Chemokines and chemokine receptors in scleroderma
Abstract
Scleroderma is a connective tissue disease with unknown etiology characterized by excessive deposition of extracellular matrix in the skin. Cellular infiltrates of certain immune cells and proinflammatory mediators are suggested to play a crucial role in cutaneous fibrosis, forming complicated networks between fibroblasts and immune cells via cell-cell communications. Tissue-selective trafficking of leukocytes is mediated by combinations of adhesion molecules and chemokines. Recent studies have shown that an increase in proinflammatory chemokines has been associated with the initiation and/or development of skin fibrosis/sclerosis, suggesting that chemokines and their receptors may be important mediators of inflammation and fibrosis in scleroderma. This review will focus on the roles of chemokines and their receptors during the process of cutaneous sclerosis and will also provide a current insight into the potential mechanisms of scleroderma.
Copyright 2006 S. Karger AG, Basel.
Similar articles
-
Pathogenic role of CCL2/MCP-1 in scleroderma.Front Biosci. 2008 Jan 1;13:2686-95. doi: 10.2741/2875. Front Biosci. 2008. PMID: 17981743 Review.
-
Potential roles of CCL2/monocyte chemoattractant protein-1 in the pathogenesis of cutaneous sclerosis.Clin Exp Rheumatol. 2003 May-Jun;21(3):369-75. Clin Exp Rheumatol. 2003. PMID: 12846061 Review.
-
Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma.Exp Dermatol. 2009 Aug;18(8):727-9. doi: 10.1111/j.1600-0625.2008.00828.x. Epub 2009 Mar 3. Exp Dermatol. 2009. PMID: 19320738
-
Cellular and molecular mechanisms of bleomycin-induced murine scleroderma: current update and future perspective.Exp Dermatol. 2005 Feb;14(2):81-95. doi: 10.1111/j.0906-6705.2005.00280.x. Exp Dermatol. 2005. PMID: 15679577 Review.
-
Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies.Acta Neurol Scand. 2007 Mar;115(3):137-46. doi: 10.1111/j.1600-0404.2006.00749.x. Acta Neurol Scand. 2007. PMID: 17295707 Review.
Cited by
-
Autoimmune mechanisms of scleroderma and a role of oxidative stress.Self Nonself. 2011 Jan;2(1):4-10. doi: 10.4161/self.2.1.14058. Epub 2011 Jan 1. Self Nonself. 2011. PMID: 21776329 Free PMC article.
-
Fibrosis in systemic sclerosis.Rheum Dis Clin North Am. 2008 Feb;34(1):115-43; vii. doi: 10.1016/j.rdc.2007.11.002. Rheum Dis Clin North Am. 2008. PMID: 18329536 Free PMC article. Review.
-
Morphea: The 2023 update.Front Med (Lausanne). 2023 Feb 13;10:1108623. doi: 10.3389/fmed.2023.1108623. eCollection 2023. Front Med (Lausanne). 2023. PMID: 36860340 Free PMC article. Review.
-
What Is New in Morphea-Narrative Review on Molecular Aspects and New Targeted Therapies.J Clin Med. 2024 Nov 25;13(23):7134. doi: 10.3390/jcm13237134. J Clin Med. 2024. PMID: 39685593 Free PMC article. Review.
-
A vitamin D analog inhibits Th2 cytokine- and TGFβ -induced periostin production in fibroblasts: a potential role for vitamin D in skin sclerosis.Dermatoendocrinol. 2015 Apr 2;7(1):e1010983. doi: 10.1080/19381980.2015.1010983. eCollection 2015 Jan-Dec. Dermatoendocrinol. 2015. PMID: 26413189 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical